Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UD4Y
|
|||
| Former ID |
DIB012158
|
|||
| Drug Name |
PQ-912
|
|||
| Indication | Dementia [ICD-11: 6D80-6D86] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N4O2
|
|||
| Canonical SMILES |
CCCOC1=CC=C(C=C1)C2CNC(=O)N2C3=CC4=C(C=C3)N=CN4
|
|||
| InChI |
1S/C19H20N4O2/c1-2-9-25-15-6-3-13(4-7-15)18-11-20-19(24)23(18)14-5-8-16-17(10-14)22-12-21-16/h3-8,10,12,18H,2,9,11H2,1H3,(H,20,24)(H,21,22)/t18-/m1/s1
|
|||
| InChIKey |
XHIKZWOEFZENIX-GOSISDBHSA-N
|
|||
| CAS Number |
CAS 1276021-65-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glutaminyl cyclase (QPCT) | Target Info | Inhibitor | [2] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02389413) Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease. U.S. National Institutes of Health. | |||
| REF 2 | Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer s Disease ImmunotherapyRoxanna Perez-Garmendia, Goar Gevorkian. Curr Neuropharmacol. 2013 September; 11(5): 491-498. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.